• Michele Gottardi, Alessandra Sperotto, Andrea Ghelli Luserna Di Rorà, Antonella Padella, Delia Cangini, Maria B Giannini, Giorgia Simonetti, Giovanni Martinelli, and Claudio Cerchione.
• IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy.
• Minerva Med. 2020 Oct 1; 111 (5): 395410395-410.

AbstractAfter being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.

47 keywords...

hide…